JP7134874B2 - 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング - Google Patents

軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング Download PDF

Info

Publication number
JP7134874B2
JP7134874B2 JP2018563394A JP2018563394A JP7134874B2 JP 7134874 B2 JP7134874 B2 JP 7134874B2 JP 2018563394 A JP2018563394 A JP 2018563394A JP 2018563394 A JP2018563394 A JP 2018563394A JP 7134874 B2 JP7134874 B2 JP 7134874B2
Authority
JP
Japan
Prior art keywords
output signal
cells
mci
biomarkers
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018563394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509500A (ja
Inventor
チリラ、フローリン・ブイ．
アルコン、ダニエル・エル．
Original Assignee
ザ・ウエスト・バージニア・ユニバーシティー・ボード・オブ・ガバナース・オン・ビハーフ・オブ・ウエスト・バージニア・ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ウエスト・バージニア・ユニバーシティー・ボード・オブ・ガバナース・オン・ビハーフ・オブ・ウエスト・バージニア・ユニバーシティー filed Critical ザ・ウエスト・バージニア・ユニバーシティー・ボード・オブ・ガバナース・オン・ビハーフ・オブ・ウエスト・バージニア・ユニバーシティー
Publication of JP2019509500A publication Critical patent/JP2019509500A/ja
Priority to JP2021091285A priority Critical patent/JP7279110B2/ja
Application granted granted Critical
Publication of JP7134874B2 publication Critical patent/JP7134874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Physiology (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018563394A 2016-02-22 2017-02-22 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング Active JP7134874B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021091285A JP7279110B2 (ja) 2016-02-22 2021-05-31 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662298182P 2016-02-22 2016-02-22
US62/298,182 2016-02-22
PCT/US2017/018810 WO2017147114A1 (en) 2016-02-22 2017-02-22 Diagnosing mild cognitive impairment (mci), predicting alzheimer's disease (ad) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021091285A Division JP7279110B2 (ja) 2016-02-22 2021-05-31 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング

Publications (2)

Publication Number Publication Date
JP2019509500A JP2019509500A (ja) 2019-04-04
JP7134874B2 true JP7134874B2 (ja) 2022-09-12

Family

ID=58361076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563394A Active JP7134874B2 (ja) 2016-02-22 2017-02-22 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング
JP2021091285A Active JP7279110B2 (ja) 2016-02-22 2021-05-31 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021091285A Active JP7279110B2 (ja) 2016-02-22 2021-05-31 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング

Country Status (5)

Country Link
US (2) US20190041404A1 (https=)
EP (1) EP3420363A1 (https=)
JP (2) JP7134874B2 (https=)
CA (1) CA3014906C (https=)
WO (1) WO2017147114A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3600027B1 (en) 2017-03-31 2026-02-18 Neurodiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease
US11621087B2 (en) * 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
CN111091906B (zh) * 2019-10-31 2023-06-20 中电药明数据科技(成都)有限公司 一种基于真实世界数据的辅助医疗诊断方法及系统

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506844A (ja) 2009-10-02 2013-02-28 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
JP2013520652A (ja) 2010-02-22 2013-06-06 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート プロテインキナーゼｃイプシロン（ｐｋｃ−イプシロン）タンパク質レベルの、アルツハイマー病に特異的な変化

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595167B2 (en) 2005-10-11 2009-09-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
EP2483684B1 (en) 2009-10-02 2018-04-18 Blanchette Rockefeller Neurosciences, Institute Fibroblast growth patterns to diagnose alzheimer's disease
US20120141498A1 (en) * 2010-12-02 2012-06-07 United States Government As Represented By The Department Of Veterans Affairs Use of pkc isozymes for diagnosis and treatment of neuroblastoma
CA2855932A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
US20170023552A1 (en) 2014-01-03 2017-01-26 Blanchette Rockefeller Neurosciences Institute Convergence of aggregation rate with validated peripheral diagnostic for alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013506844A (ja) 2009-10-02 2013-02-28 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート アルツハイマー病末梢細胞におけるｐｋｃアイソザイムプロセッシングの異常変化
JP2013520652A (ja) 2010-02-22 2013-06-06 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート プロテインキナーゼｃイプシロン（ｐｋｃ−イプシロン）タンパク質レベルの、アルツハイマー病に特異的な変化

Also Published As

Publication number Publication date
JP2019509500A (ja) 2019-04-04
JP7279110B2 (ja) 2023-05-22
JP2021156891A (ja) 2021-10-07
EP3420363A1 (en) 2019-01-02
WO2017147114A1 (en) 2017-08-31
CA3014906A1 (en) 2017-08-31
CA3014906C (en) 2025-02-18
US20240353429A1 (en) 2024-10-24
US20190041404A1 (en) 2019-02-07
US12601750B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12601750B2 (en) Diagnosing mild cognitive impairment (MCI), predicting alzheimer's disease (AD) dementia onset, and screening and monitoring agents for treating mci or preventing dementia onset
Yu et al. Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia
Buckley et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age
Snyder et al. Nonvascular retinal imaging markers of preclinical Alzheimer's disease
Davies et al. Consensus report of the Working Group on:" Molecular and Biochemical Markers of Alzheimer's Disease"
Pettigrew et al. Cortical thickness in relation to clinical symptom onset in preclinical AD
DeMaso et al. Psychiatric disorders and function in adolescents with d-transposition of the great arteries
Bilgel et al. Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample
Friedel et al. Retinal thinning in adults with autism spectrum disorder
AU2019200241A1 (en) Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
Edmonds et al. Patterns of cortical and subcortical amyloid burden across stages of preclinical Alzheimer’s disease
López et al. A multivariate model of time to conversion from mild cognitive impairment to Alzheimer’s disease
Morcillo‐Nieto et al. Characterization of white matter hyperintensities in Down syndrome
Yoon et al. Conscientiousness is associated with less amyloid deposition in cognitively normal aging.
Hansen et al. Neuropsychological comparison of incident MCI and prevalent MCI
De Riggi et al. Aging, frailty, and their effects on motor performance: evidence from kinematic analysis
Panizzon et al. Genetic architecture of learning and delayed recall: a twin study of episodic memory.
Portaccio et al. APOE-ε4 is not associated with cognitive impairment in relapsing—remitting multiple sclerosis
US11668721B2 (en) Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies
Sharon et al. Tau pathology leads to lonely non-traveling slow waves that mediate human memory impairment
Ronald et al. Consensus report of the working group on:“Molecular and biochemical markers of Alzheimer’s disease”
Alifirova et al. Prognostic Markers in Multiple Sclerosis
Massa et al. Cerebrospinal fluid NPTX2 and [18F] FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease
Gonzalez et al. Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.
Chen et al. Stable neuronal representations to repeated stimulation underlie cognitive resilience in Alzheimer’s disease pathology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200210

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211220

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211221

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220121

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220125

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220208

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20220412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220705

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220802

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220831

R150 Certificate of patent or registration of utility model

Ref document number: 7134874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250